COGTCogent Biosciences, Inc.

1. Sep 2, 2026On September 1, 2026, Cogent Biosciences, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Agreement”) with Hovione FarmaCiencia S.A. (“Hovione”) to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets (“Product”)Material agreement entered · Form 8-K
2. Aug 10, 2026As previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. (the “Company”) entered into a Sales Agreement with Guggenheim Securities, LLC (“Guggenheim Securities”), as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the …Other event · Form 8-K
3. Dec 8, 2025On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the “Company”) presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (“NonAdvSM”) and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients …Other event · Form 8-K
4. Nov 18, 2025On November 18, 2025, Cogent Biosciences, Inc. (the “Company”) completed its previously-announced public offering (the “Offering”) of $230,000,000 aggregate principal amount of its 1.625% Convertible Senior Notes due 2031 (the “Notes”), including the exercise in full of the underwriters’ over-allotment option to …Material agreement entered · Form 8-K
5. Nov 13, 2025Equity Offering On November 11, 2025, Cogent Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein …Material agreement entered · Form 8-K
6. Nov 10, 2025On November 10, 2025, the Company announced positive results from its bezuclastinib PEAK Phase 3 Trial in GIST. PEAK Phase 3 Trial Results PEAK is a global, randomized Phase 3 clinical trial evaluating bezuclastinib in combination with sunitinib vs. sunitinib monotherapy in patients with imatinib-resistant or …Regulation FD disclosure · Form 8-K
7. Sep 11, 2025On September 5, 2025, Cogent Biosciences, Inc. (“Cogent”) and BP THIRD AVENUE LLC, an affiliate of Boston Properties (the “Landlord”), entered into a lease agreement (the “Lease”) pursuant to which Cogent will lease approximately 31,518 square feet of office space in the building known as 180 CityPoint and having an …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.